The incidence of liver cancer in China is very high, because liver cancer is difficult to find in the early stage of the disease. Once the diagnosis is often in the middle and late stages, the optimal treatment time is often missed. The traditional treatment for liver cancer is surgery, radiotherapy and chemotherapy, etc. However, such treatment methods generally have a relatively high recurrence rate, and the survival rate of patients is relatively low. To prevent recurrence and metastasis of liver tumors, cell imunoterapi boleh dicuba pada masa ini.
Due to the limitation of liver tumor size, growth location, and relationship with the position of large blood vessels and biliary tract, some patients with special small liver cancer, huge liver tumor, and middle-advanced liver cancer with multiple metastatic lesions often lose the opportunity for surgery.
However, for these patients, the expert’s approach is to first use argon-helium ultra-cold knife minimally invasive treatment, through physical freezing and thawing to destroy the cell structure of tumor tissue in a short period of time, promote tumor tissue necrosis and close tumor small blood vessels. At the same time, combined with interventional therapy, embolization of tumor large vessels and local high-concentration chemotherapy, the combination of the two therapies can inhibit the growth of liver sel kanser and eliminate tumor lesions in a short period of time.
In general, most of the primary kanser hati are large undetectable liver cancers, which are accompanied by tumor thrombi in the internal and external portal vein system. The recurrence rate within one year after radiotherapy and chemotherapy is as high as 60%, and the 3-year survival rate is less than 30%. Therefore, the most important thing for liver cancer surgery is to prevent recurrence, but traditional radiotherapy and chemotherapy have large side effects, which can easily lead to liver cirrhosis and even liver function damage.
Kaedah rawatan yang agak baru-imuniti sel biologi
(sel CIK) mempunyai kesan yang ketara terhadap kanser hati peringkat lanjut. Terapi ini boleh membantu membersihkan sel-sel kanser yang tinggal dalam badan pesakit, memulihkan fungsi imun pesakit untuk mengenal pasti dan membunuh sel-sel kanser, dan dengan itu mencegah dan mengawal metastasis tumor.
Sel CIK ialah sel pembunuh yang disebabkan oleh sitokin, iaitu sel mononuklear yang diasingkan daripada darah periferal, sumsum tulang atau darah tali pusat. Selepas tempoh masa tertentu di makmal, mereka diinduksi, membiak, dan kemudian dimasukkan semula ke dalam pesakit untuk membunuh darah secara langsung, sel Tumor dalam limfa juga mengawal dan meningkatkan fungsi imun pesakit.
Menurut statistik klinikal, 9 pesakit dengan kanser hati peringkat 4 menjalani lebih daripada 3 kitaran imunoterapi sel selepas pembedahan, yang boleh mencegah berulangnya kanser hati selepas pembedahan dengan lebih baik. Purata masa kelangsungan hidup selepas rawatan ialah 20 bulan, dan kadar berulang dalam tempoh 1 tahun hanya 22.2%, dan gejala ketidakselesaan kebanyakan pesakit bertambah baik
Pemahaman mudah di atas untuk mencegah tumor hati berulang dan metastasis, anda boleh mencuba imunoterapi sel, imunoterapi sel adalah kaedah yang agak baru untuk merawat kanser, seperti imunoterapi sel biologi, boleh membantu pesakit membuang sel-sel kanser sisa dalam badan, sebagai tambahan kepada imuniti. Terapi mempunyai kesan mengenal pasti dan membunuh sel-sel kanser, seterusnya menghalang penyebaran dan metastasis tumor.
